Business Context and Reporting Period
This Form 8-K Current Report from Design Therapeutics, Inc. (DSGN) covers the date of March 31, 2026. The filing reports a corporate governance event involving the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel and compensation matters rather than financial performance.
Material Changes
The material change reported is the appointment of David Shapiro, M.D., to the Board of Directors as a Class III director, effective March 31, 2026. His term is set to end at the Company's 2027 annual meeting of stockholders. Dr. Shapiro was also appointed to the Nominating and Corporate Governance Committee.
Compensation and Governance Details
- Cash Retainer: Dr. Shapiro is entitled to an annual cash retainer of $40,000 for Board service and $5,000 for service on the Nominating Committee.
- Equity Grants:
- Initial option grant to purchase 60,000 shares of common stock, vesting monthly over three years.
- Prorated annual option grant to purchase 7,500 shares of common stock, vesting monthly over one year.
- Indemnification: The Company and Dr. Shapiro have entered into the standard indemnification agreement for directors and officers.
Investor Verification Checklist
- Verify the effective date of Dr. Shapiro's appointment and his specific committee assignments.
- Confirm the vesting schedules and total share counts for the initial and prorated option grants.
- Review the Company's non-employee director compensation policy referenced in the filing.
- Check the referenced Form 10-K filed on March 9, 2026, for the full text of the standard indemnification agreement.